Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib

Alectinib is a preferred first-line therapy for patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) in several national clinical practice guidelines. The randomized, global, phase III ALEX study has demonstrated significant improvement in progression-f...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziadziuszko, R., Peters, S., Ruf, T., Cardona, A., Guerini, E., Kurtsikidze, N., Smoljanovic, V., Planchard, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663323/
https://www.ncbi.nlm.nih.gov/pubmed/36375271
http://dx.doi.org/10.1016/j.esmoop.2022.100612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663323/
https://www.ncbi.nlm.nih.gov/pubmed/36375271
http://dx.doi.org/10.1016/j.esmoop.2022.100612

Ejemplares similares